C-EV9IRejuvenate BioMed
AI drug discovery, combination therapeutics, healthspan platforms
discoverydiscoveringsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-EV9I
C-EV9IC-EV9IAI drug discovery, combination therapeutics, healthspan platforms
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Evi Mercken, Rejuvenate Biomed, presents at the 10th Aging Research and Drug Discovery conference - Longevity Medicine Day: A combination of metformin and galantamine exhibits synergistic benefits in the treatment of sarcopenia
#longevity #biotechnology #drugdevelopment Timestamps 0:0:00 Introduction 0:07:12 How to find investors 1:07:32 The bold ambitions 2:04:00 Make therapies happen 02:52:41 Closing Remarks Session I - HOW TO FIND INVESTORS • Christian Angermayer, Co-Founder and Chairman Rejuveron Life Sciences AG • Keith Comito, Co-Founder of Lifespan.io • Kevin Perrot PhD, Co-Founder SENS foundation Session II - THE BOLD AMBITIONS • Joao Pedro de Magalhaes PhD, University of Liverpool • Vadim Gladyshev PhD, Harvard University • Matt Kaeberlein PhD, University of Washington Session III - MAKE THERAPIES HAPPEN • Ann Belien PhD, CEO Rejuvenate Biomed • Richard Barker Dphil, New Medicine Partners -- Science journalist and broadcaster, Vivienne Parry OBE, hosted the interactive panel sessions to uncover the drivers of innovation in the growing field of longevity research. -- Recording of the Rejuveron Age Better, Live Longer Symposium May 10, 2022, 05:00 PM in Zurich For more information please
Rejuvenate Biomed - Dr. Ajit Shetty appointed as Chair of the Board Home Team Science History News Events Contact Home Team Science History News Events Contact Home News Dr. Ajit Shetty appointed as Chair of the Board Rejuvenate Biomed appoints life sciences leader Dr. Ajit Shetty as Chair of the Board of Directors to help guide international ambitions Dr. Ann Beliën and Dr. Ajit Shetty Diepenbeek, Belgium, 12 May 2022 – Rejuvenate Biomed NV (“Rejuvenate”), a biomedical company developing novel combination drugs for age-related diseases, appoints Dr. Ajit Shetty as Chair of the Board of Direct … luding Agile Therapeutics, Actinium Pharmaceuticals, and reMYND), as well as VC fund Newton Biocapital. In recognition of his unique services as a leader in the life sciences industry, Dr. Shetty was awarded the Right Honourable Sir and Title of Baron by King Albert II of Belgium in 2008. He was granted the Lifetime Achievement Award in India, his country of birth, in 2010. Dr. Shetty was also elected "Manager of the Year 2004" by Belgian economic magazine Trends. Dr. Ajit Sh
3rd Value Added Medicines Conference | Medicines for Europe Who we are ABOUT MEDICINES FOR EUROPE PURPOSE AND OBJECTIVES OUR VALUES – OUR 5 PILLARS STRUCTURE MEMBERS BECOME A MEMBER CODE OF CONDUCT DISCLOSURE Vacancies PRIORITIES Key topics ACCESS INDUSTRIAL POLICY REGULATORY AND LEGAL FRAMEWORK FALSIFIED MEDICINES SUSTAINABILITY ANTIMICROBIAL RESISTANCE MEDICINE SHORTAGES Publications EXTERNAL RESOURCES FACTSHEETS INFOGRAPHICS PODCAST POLICY REPORTS VIDEOS Newsroom IN THE NEWS PRESS RELEASES Contact us --> Login Generic medicines Home Medicines for Europe Generic medicines Group MISSION AND V
Sponsors | ARDD2024 Main Past events ARDD 2025 ARDD 2024 XPRIZE Healthspan Team Summit 2024 ARDD 2023 ARDD 2022 About Speakers Speakers 2026 Speakers 2025 Speakers 2024 Speakers 2023 Speakers 2022 Program Main Track Longevity Medicine Track Emerging Science & Technologies Workshop Physics in Aging Biology Startup Pitch Replacement in Aging Workshop Molecular Nutrition Workshop ARDD Tracks Sponsorship Sponsorship Brochure Sponsors 2025 Sponsors 2024 Sponsors 2023 Sponsors 2022 Media Scam Warning Photos Videos Media Kit Photos 2025 Photos 2024 Photos 2023 Photos 2022 Vid
Rejuvenate Biomed's AI-Enabled Biopharma Advances Sarcopenia Treatment | Sachs Associates posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to jo
Speaker Interviews | Kisaco Research Skip to main content Toggle navigation Home Agenda Sponsorship Brochure Speakers Speaker Interviews Attendees Drug Developers Investors Payers CROs CDMO Provider Partners Venue Register Speaker Interviews Obesity and Metabolic Innovation Forum 4 December, 2024 Convene One Boston Place 201 Washington St, Boston, MA 02108, United States Speaker Interviews Welcome to our speaker interview series, where we bring you insightful conversations with thought leaders, industry experts, and innovators. Dive in to discover stories of success, lessons learned, and the i
Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.
Rejuvenate Biomed | BIO-Europe You need to enable JavaScript to run this app. This site is part of the Informa Connect Division of Informa PLC Informa PLC About Us Investor relations Talent This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067. November 9–11, 2026 Koelnmesse Cologne, Germany Home home Ways to attend expand_more Registration Options Company Presentation Options Delegations Program expand_more 2026 Agenda A
Amylon Therapeutics Targeting Central Nervous System Disorders Wins Startup Slam Competition at BIO-Europe Berlin - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Tr … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Amylon Therapeutics Targeting Central Nervous System Disorders Wins Startup Slam Competition at BIO-Europe Berlin November 8, 2017 | 2 min read Twitter LinkedIn Facebook Email Print Thomas de Vlaam, CEO and founder of Amylon Therapeutics, will receive a complimentary registration to BIO-Europ … sp; 2 min read · Gabrielle Masson Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst Mergers & acquisitions Serapha takes reverse merger route to Nasdaq with $230M and gene editor from China June 24, 2026 · 2 min read · Tristan Manalac Business Takeda enters transitional year as new CEO seeks return to grow … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Taking the Leap: Moving From Large to Small Biopharmas - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases A … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Career Advice Taking the Leap: Moving From Large to Small Biopharmas July 18, 2024 | 8 min read | Angela Gabriel Twitter LinkedIn Facebook Email Print Fish jumping to small bowl / Taylor Tieden for BioSpace Three executives whose combined careers include working at companies including Amg … been her biggest challenge. You have to figure out how to get money and how to apply it smartly, she noted. To tackle that challenge, Beliën shared she pitched a lot of people about her business. She also sought advice from two friends who were in the venture capitalist world, although not on the life sciences side. Those friends, she said, wound up investing in Rejuvenate. Advice for starting a company: finding the right people If you’re a biopharma professional looking to … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Rejuvenate Biomed, the NIHR Leicester BRC, and Wellcome Leap partner for Phase 2 Study in COPD-related sarcopenia - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Tr … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Rejuvenate Biomed, the NIHR Leicester BRC, and Wellcome Leap partner for Phase 2 Study in COPD-related sarcopenia October 28, 2024 | 5 min read Twitter LinkedIn Facebook Email Print The Phase 2 double-blin d placebo-controlled clinical trial will evaluate the potential of RJx-01 to maintain muscle integri … bility will be assessed. The clinical study is enabled by a multimillion dollar award from Wellcome Leap ’s Dynamic Resilience program (co-funded by Temasek Trust). The Dynamic Resilience program aims to improve biological resilience in clinically vulnerable people at-risk of adverse outcomes after a stressor event, by identifying resilience biomarkers and mechanisms and facilitating proof-of-concept studies and clinical trials of potential preventative interventions. This st … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Rejuvenate Biomed Doses First Patient in Phase 2 Trial on COPD-related Muscle Weakness and Sarcopenia - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell an … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Rejuvenate Biomed Doses First Patient in Phase 2 Trial on COPD-related Muscle Weakness and Sarcopenia May 19, 2025 | 5 min read Twitter LinkedIn Facebook Email Print The randomized, Phase 2, double-blind, placebo-controlled clinical trial will evaluate the potential of RJx-01 to maintain muscle integrity … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Rejuvenate Biomed and SAS tap AI to develop disease-agnostic drug repurposing discovery tools - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene T … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Rejuvenate Biomed and SAS tap AI to develop disease-agnostic drug repurposing discovery tools August 1, 2024 | 3 min read Twitter LinkedIn Facebook Email Print Rejuvenate Biomed to accelerate its drug development pipeline of assets for age-related diseases using jointly developed tools DIEPENBEEK, Belgium … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Rejuveron leads EUR 15.7 million Series B investment in Rejuvenate Biomed to accelerate clinical development of its sarcopenia treatment for healthy aging - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Developmen … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Deals Rejuveron leads EUR 15.7 million Series B investment in Rejuvenate Biomed to accelerate clinical development of its sarcopenia treatment for healthy aging October 11, 2021 | 4 min read Twitter LinkedIn Facebook Email Print Rejuveron Life Sciences AG today announced that it will ultimately acquir … This platform has resulted in a promising first drug candidate, with the wider application being to deliver therapeutics with a meaningful impact on the treatment and prevention of multiple age-related diseases by tackling their root causes. This strikes right at the heart of Rejuveron’s purpose: making therapies happen for people to stay healthier for longer.” Dr. Ann Beliën , PhD, Founder and CEO of Rejuvenate said: “This investment is more to us than a financial deal: it … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst Mergers & acquisitions Serapha takes reverse merger route to Nasdaq with $230M and gene editor from China June 24, 2026 · 2 min read · Tristan Manalac BioSpace is the digital hub for life science news and jobs. We provide e … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Companies that Presented at 2026 BIO-Europe Spring You need to enable JavaScript to run this app. This site is part of the Informa Connect Division of Informa PLC Informa PLC About Us Investor relations Talent This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067. March 23–25, 2026 FIL (Feira Internacional de Lisboa), Lisbon, Portugal March 31 – April 1, 2026 | Digital Partnering Home home What to expect expand_more Who a
2026 BIO International Convention | Exhibitor Floor Plan 2026 BIO International Convention Map Your Show DOWNLOAD Selected Exhibitor Search Results Available Booth Zoom In Zoom Out Max Fit Highlight Available Booths Display Booth Dimensions Orientation: Landscape Portrait Print Screenshot Include Booth Results: None Search Results Include Exhibitor Names on Floor Plan: Yes Print Hall(s): Current Hall All Halls Show Available Booths Your floor plan printout is processing. If you selected multiple halls it may take a minute for your print to finish. Loading... Creating Printout..... PRINT MY FLO
Ann Beliën - BIO International Convention 2026 Start your engines! BIO 2026 is June 22-25 at the San Diego Convention Center. Program announced! See the 130+ sessions in 18 focus areas. Generate Your Personal Event Schedule in Seconds! GENERATE NOW Start your engines! BIO 2026 is June 22-25 at the San Diego Convention Center. Program announced! See the 130+ sessions in 18 focus areas. Generate Your Personal Event Schedule in Seconds! GENERATE NOW June 22-25 | San Diego Event Info Event Overview About BIO International Convention Future dates Attendee Policies Schedule at a Glance FAQs I … ific Progress AI Implementation Biomanufacturing Academia Company Presentations Apply for a Company Presentation 2026 Presenting Companies Curated Programs AI Summit BIO Storytelling Stage BioProcess Theater Global Innovation Hubs Professional Development Courses Start-Up Stadium Student Program BIO Partnering™ BIO Partnering™ at BIO 2026 BIO Partnering™ Overview Pre-Event Webinars Partnering Resources LOG IN TO BIO PARTNERING Participating Companies All Partnering Companies … Amgen Genentech Boehringer Ingelheim Lilly Novo Nordisk Sanofi Academic Campus Apply for Academic Campus Exhibition Directory and Map Event Directory Exhibitor List Exhibitor In-Booth Events Event Map Exhibition Hours Exhibition Reception BIO Booths BIO Business Solutions® Pavilion BIO Member Lounge Networking BIO Receptions Other Events Social Spotlight Events Affiliate Events Application Special Experiences 5K and 1 Mile Course BIO Gives Back Headshot Lounge Matchday Loung
Rejuvenate and SAS partner to harness AI for age-related diseases - Pharmaceutical Technology Skip to site menu Skip to page content Switch language: .translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Pharma Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insights Dea
Watch lectures from the best researchers. | Underline Reception Schedule Sessions Posters Expo log in Powered by underline ISTRC 2021 - International Sarcopenia Translational Research Conference log in Rejuvenate Biomed Please select the button and submit the requested information to connect with the sponsor. contact us X Linkedin Website Email Rejuvenate Biomed is an independent Belgian biomedical company founded in 2017 by Dr. Ann Beliën, after nearly two decades of experience at Janssen Pharmaceutical companies of Johnson and Johnson. The Rejuvenate Biomed team brings together over 100 year … ad life science venture capital investor on board. Please select the button and submit the requested information to connect with the sponsor. contact us
About the Intrinsic Capacity, Frailty and Sarcopenia Research Conference for Healthy Longevity | Rejuvenate Biomed LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign
Rejuvenate Biomed - Team Home Team Science History News Events Contact Home Team Science History News Events Contact Home Team Meet our innovators Our mission is to evaluate the therapeutic potential of safe compounds to develop proprietary combination drugs that impact the onset of age-related diseases by influencing the aging process. Board of Directors Ajit Shetty, PhD Chair of the Board View profile Ann Beliën, PhD Director of the Board, Founder View profile Stéphane Verdood, MBA Director of the Board View profile Glenn Van Dael Director of the Board View profile Leadership Team Ann Beliën
Instagram Instagram Log In Sign Up Close Never miss a post from senapsymposium Sign up for Instagram to stay in the loop. Sign up Log in senapsymposium • Follow More options senapsymposium 50w 💰 Meet the sponsors of SenAP Symposium 2025! 💎 Platinum sponsor: - Rejuvenate Biomed: AI-enabled clinical-stage biotech dedicated to the discovery and development of therapeutics to impact the onset of multiple age-related diseases 🥈 Silver sponsors: - UHasselt Doctoral schools: The doctoral schools provide support for early-career researchers by organizing training and coaching, by encouraging and en
Rejuvenate Biomed Secures EUR 3.2 Million Series A Round to Advance Development of Healthy Aging Products - BioVox Skip to content Field of application Agrofood Biomedical/pharma Environment/sustainability Personal/public health Veterinary science Focus on Discovery & research Finance & investment Industrial application Technology & digital innovation Content type Article Interview News Opinion Press release Showcase BioVox Biovia QbD Group V-Bio Ventures SciMingo JnJ Innovative Medicine Regional news Belgium Flanders Wallonia Luxembourg The Netherlands Field of application Agro … science Focus on Discovery & research Finance & investment Industrial application Technology & digital innovation Content type Article Interview News Opinion Press release Showcase BioVox Biovia QbD Group V-Bio Ventures SciMingo JnJ Innovative Medicine Regional news Belgium Flanders Wallonia Luxembourg The Netherlands Subscribe Calendar About Learn more about BioVox Contact Calendar About Learn more about BioVox Contact Search Subscribe Calendar About Learn mor … re about BioVox Contact Calendar About Learn more about BioVox Contact Field of application Agrofood Biomedical/pharma Environment/sustainability Personal/public health Veterinary science Focus on Discovery & research Finance & investment Industrial application Technology & digital innovation Content type Article Interview News Opinion Press release Showcase BioVox Biovia QbD Group V-Bio Ventures SciMingo JnJ Innovative Medicine Regional news Belgium Flanders W … ine Regional news Belgium Flanders Wallonia Luxembourg The Netherlands Field of application Agrofood Biomedical/pharma Environment/sustainability Personal/public health Veterinary science Focus on Discovery & research Finance & investment Industrial application Technology & digital innovation Content type Article Interview News Opinion Press release Showcase BioVox Biovia QbD Group V-Bio Ventures SciMingo JnJ Innovative Medicine Regional news Belgium Flanders W … pital III Vesalius Biocapital III is a specialist life sciences venture capital fund in line with predecessor funds Vesalius Biocapital I and Vesalius Biocapital II, which have supported life sciences companies since 2007. Vesalius Biocapital I and II contributed to the development of over 20 companies. Vesalius Biocapital III, launched in April
Drug discovery companies partner to overcome challenges - Drug Discovery World (DDW) Drug Discovery World (DDW) About Us | Subscribe Free | Media Info | Contact Us | Log In News Exclusive Content Features Opinion Market Reports Trends & Analysis Start-up Zone DDW eBooks Business & Investment Regulatory Events Webinars Resources Magazine Digital Issues Archive Multimedia Videos Podcasts Topic filter: Cancer Research Immunology / Virology & Vaccines Advanced Therapies Neuroscience Multiomics Artificial Intelligence Automation & Robotics Therapeutic Antibodies Microbiome Drug Discover … te exacerbation of COPD. The clinical study is enabled by a multimillion dollar award from Wellcome Leap’s Dynamic Resilience programme (co-funded by Temasek Trust). It will be led by Dr Neil Greening and Dr Hamish McCauley from the NIHR Leicester BRC at University Hospitals of Leicester NHS Trust. Dr Greening said: “Findings ways to maintain muscle function is increasingly important, which is why we’re delighted to be working with Rejuvenate Biomed and on this world-fi
Small country, big science: how Belgium’s industrial past fuelled its biotech future BioPitch Subscribe Sign in Small country, big science: how Belgium’s industrial past fuelled its biotech future With insights from Ablynx, Baker McKenzie, Rejuvenate Biomed, Van Lanschot Kempen, V-Bio Ventures, and VIB, this article unveils the formula behind Belgium's success within the biotechnology sector. Yilmaz Biter Jan 26, 2026 11 3 4 Share Welcome to the Biotech Atlas series, which maps the diverse and dynamic life sciences ecosystems that are shaping our world today. As well as exploring the science i … collaboration over competition, the government also created a specific biotech fund that could be professionally managed. The Biotech Fonds Vlaanderen (BFV) was founded in 1995 with an initial capital of 25 million euros and was initially managed by a team of Gimv. BFV investments have enabled companies such as Ablynx, Actogenix, AgroSavfe, Complix, CropDesign, Devgen, Galapagos, Innogenetics, Movetis, Multiplicom and Plant Genetic Systems (PGS) to start up or grow. ‘’The go … netic Systems (PGS) to start up or grow. ‘’The government also ensured that the fund invested in both companies and as a limited partner (LP) in VC funds. The idea was that the government would invest as a limited partner (LP) in funds outside Belgium, thereby bringing that expertise into Belgium. This professionalised the environment, benefiting the founders.’’ Jan De Kerpel By contrast, Wallonia’s support evolved later and remained more sensitive to shifting ministerial age … ty of Antwerp, the University of Hasselt and the Vrije Universiteit Brussel. We fund top researchers at these universities, who then become part of VIB. This makes us a de facto partnership and joint venture with the universities. The key difference is that VIB controls the joint intellectual property (IP) and valorisation efforts. We have the exclusive mandate to manage and commercialise the research and joint IP or potential partners, such as investors and biotech and pharm … ). According to corporate finance lawyer Younes Sebbarh (Baker McKenzie), these grant programmes provide vital support in the early stages. ‘’Public investors like PMV in Flanders, Wallonie Entreprendre in Wallonia, and federal players like SFPIM play an important role by co-investing alongside private capital. However, despite this support, gaps
%PDF-1.7 %���� 1 0 obj >/Metadata 125 0 R/ViewerPreferences 126 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 612 792] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��Z�r�6}w��o!�F x�J%5�g�L&��k�!��)Y�B��ƿ�?��@B��l:��L �q��{{��W��/��p����~�W T�� ?�_}�N�N�o�Gq�_��Y �Y!X���>��U�G'�Go���#�.���8,�gY e�b�Q���5,�� z{�r|�&r�}&�6��5�MGG=>lOg�hb2�E��?�y�(� 5N��+|�^k}��l��> Ǘ0Z�#��"�n�ҧSjw�S�F�K� ���5Jo���p��gJ �12NĭQ�� q Ѷ��km���U���h&�V.��[�X �B p�o�K4���P%@~SQ扈���
Rejuvenate Biomed completes enrollment in sarcopenia trial Skip to content News Data Podcast Clinics News Data Podcast Clinics Search Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Advertise NEWSLETTER News Data Podcast Clinics News Data Podcast Clinics Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire About Contact About Contact Advertise nEWSLETTER Search Search Next Health opens flagship ... BCI
Rejuvenate Biomed - Advisory Board endorses clinical Ph 2b strategy Home Team Science History News Events Contact Home Team Science History News Events Contact Home News Advisory Board endorses clinical Ph 2b strategy Press release Rejuvenate Biomed’s newly appointed Clinical Advisory Board endorses Clinical Phase 2b strategy in sarcopenia Diepenbeek, Belgium, 15 November 2022 – Rejuvenate Biomed NV (“Rejuvenate”), a biomedical company developing novel combination drugs for age-related diseases, organized a Clinical Advisory Board meeting to discuss the clinical development of lead candidate R
Rejuvenate Biomed - Publication of animal data on RJx-01 Home Team Science History News Events Contact Home Team Science History News Events Contact Home News Publication of animal data on RJx-01 Press release Rejuvenate Biomed announces publication of data showing that RJx-01 significantly increases muscle mass, muscle strength and physical performance in sarcopenia mouse models Sarcopenia – age-related loss of muscle mass and strength – affects up to 1 in 5 elderly people globally i but there are no approved drugs The newly-published data validate the predictive value of Rejuvenate Biomed’s
Rejuvenate Biomed - Evi Mercken, PhD Home Team Science History News Events Contact Home Team Science History News Events Contact Home Team Evi Mercken, PhD Evi Mercken, PhD Evi Mercken, PhD Chief Scientific Officer Dr. Evi Mercken is CSO at Rejuvenate Biomed and a member of the management board. As CSO, she provides strategic and scientific leadership across a range of R&D activities, including in-silico tools, cell culture models, C. elegans platforms, and preclinical mouse studies. With nearly 20 years of international experience in the field of aging, Evi brings deep expertise in transl
Vesalius Biocapital III | Rejuvenate Biomed raises €15.7 million To content . Investor Portal Menu Home Team Fund 3 News Fund 3 Sustainability-related disclosures Contact . Rejuvenate Biomed raises €15.7 million Rejuvenate Biomed raises a EUR 15.7 million Series B to accelerate clinical development of its sarcopenia treatment for healthy aging Heusden-Zolder, Belgium, Schlieren, Zürich, Switzerland, and Luxembourg, Grand Duchy of Luxembourg, 12 October 2021 – Rejuvenate Biomed NV ('Rejuvenate'), a biomedical company developing novel combination … This platform has resulted in a promising first drug candidate, with the wider application being to deliver therapeutics with a meaningful impact on the treatment and prevention of multiple age-related diseases by tackling their root causes. This strikes right at the heart of Rejuveron's purpose: making therapies happen for people to stay healthier for longer." About Rejuvenate Biomed Rejuvenate Biomed is an independent Belgian biomedical company established in October 2017 … pital III Vesalius Biocapital III is a specialist life sciences venture capital fund in line with predecessor funds Vesalius Biocapital I and Vesalius Biocapital II, which have supported life sciences companies since 2007. Vesalius Biocapital III, launched in April 2017, announced a final close with EUR 120 million in commitments. The fund targets later-stage European life science companies in drug development, medtech, diagnostics and digital health. The specialist team is b
Rejuvenate Biomed In the fight against ageing - Belgian Research 📰 191 articles published : view all ★ Plus de 150 structures et experts déjà en ligne Home European Commission Federal Ministries Centres of expertise Flanders Ministries Regions Higher education Hospitals Partners Brussels Ministries Regions Higher Education Hospitals Partners Wallonia Ministries Regions Higher Education Hospitals Partners Partners Contact Menu Flanders Partner Publication date : 7th March 2022 Views : 687 PDF Rejuvenate Biomed In the fight against ageing Everyone dreams of a healthy and vital old age. A young
University of Leicester - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 04 Jun 2026 University of Leicester Education | 1957 | United Kingdom | 1,000-5,000 | www.le.ac.uk Education | 1957 | United Kingdom | 1,000-5,000 | www.le.ac.uk Last update 04 Jun 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Neoplasms Skin and Musculoskeletal Diseases Respiratory Diseases Proteolysis-targeting chimeras (PROTAC) Small molecule drug Synthetic peptide Disease dom … ne model to enable timely specialist consultations, and a patient-facing mobile application-supported by community champions and care coordinators to enhance care coordination, self-management, and treatment adherence. At this stage, we have completed the case-mix and health facility assessments, alongside the in-depth interviews to identify challenges faced by patients, caregivers, and health care providers. Currently, we are pilot testing the health intervention in 4 PHCs i … ronic clinical decision support system, assisted telemedicine, a patient-facing application, and community champions. The study will be conducted across selected sites in India and Nepal using a cluster randomized controlled design, in which Primary Health Centres (PHCs) are allocated to either the intervention or usual care arm. The intervention includes structured clinical workflows, a digital decision support system, assisted telemedicine, and patient-facing mobile health … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
Mergers & Acquisitions articles and careers information on BioSpace Skip to main content Skip to main menu Skip to user menu Jobseeker Sign in News Drug Development FDA Drug Delivery Deals Business Policy Cell and Gene Therapy Weight Loss Rare Disease Cancer Job Trends Artificial Intelligence NextGen: Top Start Ups To Watch Podcasts Reports Webinars Press Releases All News & Releases Insights Jobs Search Jobs Job Alerts Jobseeker Sign In Career Advice Companies Hotbeds More Best Places to Work Employer Resources Post Jobs Talent Solutions Advertise Submit a Press Release Subscribe Subscrib … icy More Employer Login Employer Resources Post Jobs Talent Solutions Advertise Submit a Press Release RSS Feeds Facebook This will open in a new window Twitter This will open in a new window LinkedIn This will open in a new window Instagram This will open in a new window © 1985 - 2026 BioSpace.com. All rights reserved. Powered by Madgex Job Board Software
Rejuvenate Biomed - Groundbreaking clinical trial started Home Team Science History News Events Contact Home Team Science History News Events Contact Home News Groundbreaking clinical trial started Press release Rejuvenate Biomed started Groundbreaking Clinical Trial and expands for Future Growth • Started clinical trial with lead candidate RJx-01 for treating sarcopenia • Expands the team and moved to new offices and lab Diepenbeek, Health Campus, Belgium, 29 March 2022 – Rejuvenate Biomed NV (“Rejuvenate”), a biomedical company developing novel combination drugs for age-related diseases, tod
Rejuvenate Biomed - Executive Bio, Top Executies, and Transitions - Equilar ExecAtlas Request a Demo Engage Executives. Unlock Deals. ExecAtlas delivers real-time insight into who-knows-who, paving the way for warm introductions that create opportunities. Search for an Executive Trusted by Industry Leaders Trusted by Industry Leaders Featured Organization Rejuvenate Biomed rejuvenatebiomed.com Company Details Description Rejuvenate Biomed is a biomedical company researching the biology of aging & applying this knowledge to identify safe and well tolerated drugs to maintain and restore our … ; Johnson in 2000. Prior to her tenure at J&J, she completed a postdoctoral fellowship at ETH Zurich in Switzerland. Dr. Beliën holds a PhD from the University of Zurich, Switzerland, and a master’s degree from the Free University of Brussels (VUB), Belgium. Read More Lizzy-Anne Neven Chief Financial Officer Lizzy-Anne Neven is CFO of Rejuvenate Biomed and additionally, responsible for HR. She is member of the Executive team and invited guest of the Board of Directors of … ; Johnson in 2000. Prior to her tenure at J&J, she completed a postdoctoral fellowship at ETH Zurich in Switzerland. Dr. Beliën holds a PhD from the University of Zurich, Switzerland, and a master’s degree from the Free University of Brussels (VUB), Belgium. Read More Lizzy-Anne Neven Chief Financial Officer Lizzy-Anne Neven is CFO of Rejuvenate Biomed and additionally, responsible for HR. She is member of the Executive team and invited guest of the Board of Directors of
Centenara Labs (formerly Rejuveron) | Catalio Capital Portfolio Home Strategies Overview Private Equity Structured Opportunities Public Equities Co-Investments Portfolio Team News Investor Login SEI Login MSFS Login Investor login SEI Login MSFS Login [Portfolio] Centenara Labs (formerly Rejuveron) Visit website Centenara Labs is a “hub and spoke” biotechnology company combating age-related diseases. Centenara Labs has built a diversified portfolio, acquired or developed internally, with the potential to not only address age-related diseases with high unmet need, but address the underlying hal … ation by replying HELP. Message frequency varies and message and data rates may apply. You may review our Privacy Policy to learn how your data is used. Thank you! Your submission has been received! Something went wrong while submitting the form, please try again. Information Terms of Use Privacy Policy Security For Investors SEI Login MSFS Login Thank you! Submission received! Something went wrong, try again. ↑ Catalio Capital Management, LP | © 2026
Rejuvenate Biomed N.V. - [LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal Zum Inhalt News People Events Deals Organisations Newsletter About us Contact Top News AMD, Dell & Univ Cambridge Launch UK AI Innovation Lab Caszyme: WiFIX Consortium Awarded €1m Eurostars Grant GSK to Acquire Nuvalent for $10.6b in Cash Merck Appoints Two Life Sciences Leadership Team Members Fusix Biotech & Recipharm Advance Oncolytic Virus Platform Roche and Nurix: up to $2.3b Agreement for BTK Degrader AMD Commits up to £2b to Accelerate AI in UK DaltonTx Launches Platform and Partners with Syg … to Biosciences and DaltonTx: AI-Driven Collaboration » More News! » Submit your News! Upcoming Events UBS Life Sciences Conference 2026 London Metabolomics 2026 Buenos Aires BIO 2026 San Diego (BIO International Convention) TD Cowen’s Tools/Dx Revolution Conference 2026 Dana Point Truist Securities Healthcare Disruptors & Digital Health Conference 2026 New York LSI Asia ’26 Emerging MedTech Summit 2026 Singapore Longevity Summit Dublin 2026 European Spatial Comput … f America Global Healthcare Conference London 2026 » More Events! » Submit your Event! Management Appointments Endress+Hauser Appoints Christian Mäder as Future CFO Orlando Oliveira Succeeds Dario Eklund as CEO of Santhera Clara Sattler de Sousa e Brito Joins Merck (DE) from Philips Evotec Nominates Dieter Weinand as Supervisory Board Chair Santhera Appoints Marc Clausse as Chief Commercial Officer Fujifilm Biotechnologies Appoints Christiane Bardroff as CBO Camil … n Bulling Joins ProBioGen as Chief Operating Officer » More News! » Submit your News! Financings & Acquisitions Ona Therapeutics Raises $86.6mSeries B to Advance ADCs Olix Pharma Secures KRW110b Investment from BOLD and Weiss T-Curx GmbH Acquires Pantherna Therapeutics GmbH Genovis Acquires KPL ApS for DKK30.5m Upfront plus Earn-outs Lilly to Acquire LimmaTech Biologics for up to $780m in Cash InSphero Acquires PhenoVista Biosciences to Expand in US Lauxera Capita … henoVista Biosciences to Expand in US Lauxera Capital Partners Closes Growth II Fund at €520m Metis TechBio: $270m IPO at Hong Kong Stock Exchange NanoStruct Closes €2.6m Seed Round Led by HTGF et al. Roche to Acquire PathAI for up to $1.05b » More News! » Submit your News! Collaborations & Licensing Roche and Nurix: up to $2.3b Agree
Rejuvenate Biomed - Stéphane Verdood, MBA Home Team Science History News Events Contact Home Team Science History News Events Contact Home Team Stéphane Verdood, MBA Stéphane Verdood, MBA Stéphane Verdood, MBA Director of the Board Stéphane Verdood s Managing Partner of Vesalius Biocapital Fund 1, Fund 2 and Fund 3 and Lead Partner for Apitope, FF Pharma, Genkyotex (reverse merger with Genticel, now Euronext-quoted), Genomic Vision (Euronext-quoted) and Trod Medical. He has over 26 years of experience in the life sciences industry. Stéphane was Founder and Managing Partner at Value4Growth, a s
#ardd25 #ardd2025 #agingresearch #pharma #biotech | Rejuvenate Biomed LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement ,
Rejuvenate Biomed - €3.2 million Series A round secured Home Team Science History News Events Contact Home Team Science History News Events Contact Home News €3.2 million Series A round secured Rejuvenate Biomed secures €3.2 million Series A round Heusden-Zolder, Belgium, 2 March 2021 – Rejuvenate Biomed NV (“Rejuvenate”), a biomedical company developing prescription drugs for age-related diseases, announces it has completed a EUR 3.2 million Series A round. The funding is being used to advance the development of Rejuvenate’s lead candidate RJx-01 in both acute and chronic sarcopenia (disuse-i … pital III Vesalius Biocapital III is a specialist life sciences venture capital fund in line with predecessor funds Vesalius Biocapital I and Vesalius Biocapital II, which have supported life sciences companies since 2007. Vesalius Biocapital I and II contributed to the development of over 20 companies. Vesalius Biocapital III, launched in April 2017, announced a final close with EUR 120 million in commitments. The fund targets later-stage European life science companies in d
First subject dosed in Rejuvenate's muscle weakness trial Skip to site menu Skip to page content Switch language: .translate --> CT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Approvals Operations Outsourced Services Supply Chain Data Management Medical Devices Themes Artificial Intelligence Cloud Corporate Governance Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insights Deals Jobs Filings Patents Social Media Companies Company A-Z Company Categories Product & Ser
Rejuveron leads €15.7m series B in Rejuvenate Biomed Skip to content News Data Podcast Clinics News Data Podcast Clinics Search Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Advertise NEWSLETTER News Data Podcast Clinics News Data Podcast Clinics Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire About Contact About Contact Advertise nEWSLETTER Search Search TrimTech adds $14m in fundi... Winona st … This platform has resulted in a promising first drug candidate, with the wider application being to deliver therapeutics with a meaningful impact on the treatment and prevention of multiple age-related diseases by tackling their root causes. This strikes right at the heart of Rejuveron’s purpose: making therapies happen for people to stay healthier for longer.” Dr Ann Beliën, PhD, Founder and CEO of Rejuvenate said: “This investment is more to us than a financial deal; it is … e menopause symptoms simultaneously GARM Clinic launches first Klotho longevity residency in Roatan Cognito’s wearable device boosts brain proteins linked to Alzheimer’s protection Lys Therapeutics raises over $27m to advance new treatments for Parkinson’s and stroke RELATED ARTICLES Peers Capital bets on prevention before the pivot Stem cell banking partnership targets future of longevity Insilico’s $2.5b AI drug discovery deal targets neuroimmune failure Y … research (and opinions)? Harness’ two-pronged Parkinson’s program secures MJFF grant Brain health ‘collaboratory’ focuses on non-invasive Alzheimer’s therapy Perplexity enters the consumer health AI arena Startup targets ‘untreatable blindness’ with bionic eye system Science Corp lands $230m to commercialize vision restoration chip MUSCLE: FLT’s revolutionary AI-powered supplement for strength and longevity Ergothioneine: The little-known molecule tra
Rejuvenate Biomed and SAS tap AI to develop disease-agnostic drug repurposing discovery tools | WebWire News and Press Release Distribution, Since 1995 Deliver Your News to the World Sign In Create a Free Account Home News How We Work Compare Services FAQ All WebPost WebRelease Targeted Media Wire Service Rejuvenate Biomed and SAS tap AI to develop disease-agnostic drug repurposing discovery tools Rejuvenate Biomed to accelerate its drug development pipeline of assets for age-related diseases using jointly developed tools Cary, NC and Diepenbeek, Belgium – WEBWIRE – Thursday, Augus … numerous highly trafficked news search engines generating leads and publicity. Submit Your Release Now! To fix IE DIVs clearing --> WebWire® 1995 - 2026 About Us Terms of Service Privacy Statement
Instagram Instagram Вход Регистрация Затваряне Никога не пропускайте публикация от ftpartnercontent Регистрирайте се за Instagram, за да останете информирани. Регистрация Вход ftpartnercontent Потвърдено • Следване Още опции ftpartnercontent Потвърдено 53 седм. How Covid-19 fundamentally altered the Biotech funding landscape. Dr. Ann Beliën (Founder and CEO of Rejuvenate Biomed) on the new episode of The Next Five featuring Paul Little (CEO of @vesperbio ) and Gianmario Verona (President at @humantechnopole ). Listen now at thenextfive.ft.com or wherever you get podcasts. Зареждане на още коме
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
🎉 Exciting news! Ann Belien, PhD, founder & CEO of Rejuvenate Biomed, presented yesterday at the Raymond James Biotech Private Day (virtual). A great opportunity to get our message out to Wall… | Rejuvenate Biomed LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices
Ann Belien - Rejuvenate Biomed | BIO-Europe Spring Speaker You need to enable JavaScript to run this app. This site is part of the Informa Connect Division of Informa PLC Informa PLC About Us Investor relations Talent This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067. March 23–25, 2026 FIL (Feira Internacional de Lisboa), Lisbon, Portugal March 31 – April 1, 2026 | Digital Partnering Home home What to expect expand_mo
Rejuvenate Biomed - Ann Beliën, PhD Home Team Science History News Events Contact Home Team Science History News Events Contact Home Team Ann Beliën, PhD Ann Beliën, PhD Ann Beliën, PhD Director of the Board, Founder Dr. Ann Beliën is the Founder and CEO of Rejuvenate Biomed, a company she established in 2017. Over the past eigth years, she has transformed the organization from a discovery-phase start-up into a clinical-stage company, assembling a dynamic team of 20 experts and successfully securing international investments, from seed funding through Series B. With over 25 years of extensive … ; Johnson in 2000. Prior to her tenure at J&J, she completed a postdoctoral fellowship at ETH Zurich in Switzerland. Dr. Beliën holds a PhD from the University of Zurich, Switzerland, and a master’s degree from the Free University of Brussels (VUB), Belgium. View LinkedIn Profile Rejuvenate Biomed is an AI-enabled clinical-stage company developing combination drugs to promote healthy aging. LET'S CONNECT Agoralaan A-bis 3590 Diepenbeek Belgium View map One Broadway,
Rejuvenate Biomed - Lizzy-Anne Neven Home Team Science History News Events Contact Home Team Science History News Events Contact Home Team Lizzy-Anne Neven Lizzy-Anne Neven Lizzy-Anne Neven Chief Financial Officer Lizzy-Anne Neven is CFO of Rejuvenate Biomed and additionally, responsible for HR. She is member of the Executive team and invited guest of the Board of Directors of Rejuvenate Biomed. She brings more than 30 years of experience in finance & taxes, accounting, merger and acquisition. As CEO and co-founder of Kantoor Nege, an accountancy and tax office, she was in charge of the ex
Rejuvenate Biomed Completes Recruitment in Phase 2 Trial --> Accessibility: Skip TopNav Rejuvenate Biomed Completes Recruitment in Phase 2 Trial Assessing First-in-Class Multi-Pathway Therapeutic RJx-01 in COPD-Induced Sarcopenia June 01, 2026 06:00 ET | Source: Rejuvenate Biomed NV Rejuvenate Biomed NV Fully recruited Phase 2 trial evaluates RJx-01 in older adults with COPD-induced muscle weakness and sarcopenia, an area with no approved pharmacologic treatments RJx-01 offers a multi-pathway approach targeting several drivers of muscle decline, including mitochondrial dysfunction, infl
News To content . Investor Portal Menu Home Team Fund 3 --> News Fund 3 Sustainability-related disclosures Contact . Rejuvenate: Potential of RJx-01 Diepenbeek, Belgium, February 21st, 2024 – Rejuvenate Biomed NV ("Rejuvenate Biomed") , a pioneering clinical-stage platform and pipeline company committed to enhancing lifelong health through innovative therapeutics, today announces breakthrough functional outcome results from its Phase 1b trial of lead candidate RJx-01 for the treatment of sarcopenia. Caresyntax: Healthcare‘s Fierce 15 SAN FRANCIS
Instagram Instagram Log In Sign Up Close Never miss a post from ftpartnercontent Sign up for Instagram to stay in the loop. Sign up Log in ftpartnercontent Verified • Follow More options ftpartnercontent Verified 53w How Covid-19 fundamentally altered the Biotech funding landscape. Dr. Ann Beliën (Founder and CEO of Rejuvenate Biomed) on the new episode of The Next Five featuring Paul Little (CEO of @vesperbio ) and Gianmario Verona (President at @humantechnopole ). Listen now at thenextfive.ft.com or wherever you get podcasts. Load more comments No comments yet. Start the conversation. Like 7
All Rejuvenate Biomed articles | Drug Target Review Your browser is not supported Sorry but it looks as if your browser is out of date. To get the best experience using our site we recommend that you upgrade or switch browsers. Find a solution Skip to main content Skip to navigation Site name Site name Mast navigation Become a member Sign In Search our site Search our site Search Menu Close menu Home News Oncology AI Topics Back to parent navigation item Topics Technology Resources Diseases Drugs and therapies Research and development Tools and techniques Business Webinars Whitepapers Reports
Rejuvenate Biomed and SAS tap AI to develop disease-agnostic drug repurposing discovery tools | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
#startups #longevity #healthy #lifespan #healthyaging #startup #aging #drugdevelopment | Rejuvenate Biomed LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you
POM Limburg promoot Health Campus in San Francisco - Health Campus Health Campus Community Nieuws Zorginnovatiefonds Contact Health Campus Community Nieuws Zorginnovatiefonds Contact Terug naar overzicht POM Limburg promoot Health Campus in San Francisco POM Limburg is samen met enkele Limburgse bedrijven, waaronder Van Havermaet en Rejuvenate Biomed, aanwezig op de JP Morgan Healthcare Conference in het Amerikaanse San Francisco. Het evenement, dat wereldwijd bekend staat als één van de meest prominente in de zorgsector, biedt een uitgelezen kans o De JP Morgan Healthcare Conference in San Fr
BIO International Convention | BIO | Rejuvenate Biomed LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy
Rejuvenate Biomed - Events Home Team Science History News Events Contact Home Team Science History News Events Contact Home Events Where can you meet us? Podcast with Rejuvenate Biomed: HBvL Xtra: Hoe veelbelovend is the 'antiverouderingspil' van Diepenbeeks bedrijf? Podcast with Rejuvenate Biomed: The BioHub Podcast Upcoming events BIO International Convention Jun 22, 2026 - Jun 25, 2026 Panel & Presenting (San Diego) BIO 2026 is where we return to this essential "why." It is our opportunity to reconnect as a global community, to recharge our commitment, and to remembe … able insights into bridging the gap between scientific advancement and clinical application. MORE INFO BioJapan 2023 Oct 11, 2023 - Oct 13, 2023 Exhibitor and speaker (Yokohama, Japan) Asia's premier partnering event, focusing on providing new value by business partnering of industry, academia, and government from over the world. Ann Beliën, CEO, will present "Rejuvenate Biomed initiating sarcopenia phase 2 study for its lead candidate as identified through propriet … d and strengthen business network for future partnerships. MORE INFO Successful Grant Writing: Common Challenges and How to Overcome Them Feb 10, 2020, 10:45 AM Speaker (Beerse, Belgium) In this workshop, we will present some of the main grants available for life science entrepreneurs in Europe, and we will talk about some of the main pitfalls in finding grants, writing applications and managing grant projects, and show you how to avoid them. MORE INFO Value Added Medicines C
Rejuvenate Biomed - Rejuvenate Biomed and SAS tap AI to develop disease-agnostic drug repurposing discovery tools Home Team Science History News Events Contact Home Team Science History News Events Contact Home News Rejuvenate Biomed and SAS tap AI to develop disease-agnostic drug repurposing discovery tools Press Release Rejuvenate Biomed and SAS tap AI to develop disease-agnostic drug repurposing discovery tools Rejuvenate Biomed to accelerate its drug development pipeline of assets for age-related diseases using jointly developed tools DIEPENBEEK, Belgium and CARY, N.C. (August 1, 2024) - R
%PDF-1.5 %���� 4 0 obj > stream x���[w,��&�^�"���Yfu� ��� �"�E�����~-r?n�H� �ْ�~�"V2 �]��0.H4d9uLN����Y� � �v�xZ�zL���Gd��jܝ��!�� �� ��)�n:D �0i���V;D}�!�ԑ��T��.Xj����ܝ� T�_hk�ie��t�I�W�ĴV�u� ��������j�i�:����u�n����05}5LM? SPL�®��5�5LMa S��Ԇa����:McE�� �ihC3��Be���ʫf��X���p�/���p[�p% ��Tv�l����aj*k�LE �\V ==>��>h�� ��bZ���|�� '"�}��ѻ�����a�Lw�������O��D��|�1�F��i�Q����\)�9�@��!��9�p+��C�>�$1�)r��7q���Q���8��a{�L�@Z>H�PI �Խ����E4v��/ p���\R����q�G]��������X���H�>�^hX �Ϗ�����O ��M ��]\?==?���n�_�p�8�>���~��O��N������:#����$��w{8��y�)�z��r��Gu� �#�dY���y��=?> … \y����#ˑX�nZ�� �8�YC$�0�U�� �G ��h��x�y����א�\SZ��� [J+&�S�Ҽ�M/f�:�ϙjf�RFp�k����K�@Q��UZ"Q�=���pNkyϚ$�6e7� �4�6H�=�� Z��n��4Й�j��H\��d�&�4e�I���p*c~�8$�:8����XHJ�v�q�t0c?ZE�L.)a�D��ք��N-:% ���nl�٣C� �T��6�d����ȪV{��u&�܈T`�$�M�RV�Ѳ�b��Q� s 1 �Ԓz f�:C;e���h�2J� 7�m�{�t�8�Z���D"�c1$�%���5 C�ud���� t���2y�M� ���Ey�g�A銨R� �Y���%��"9Y�;s��D�7���?��� Q9)Ԟ3\KcW�����&�3��NqN|�� K��g.��Al�A$� ��B���P�eT��5�v�XR�a���Q��|E����| �g V٦*z${�|3� … #�s>T���B��M>� U*�6ʽ"���pk�Ye [c7��B�I�eO/�6�OT�"�h�m0�1����M�-Q�� �O����4�rfp�8=���0��� w8�,�J��t? N-h|� Ʊ+�N�q���ZRT�eC��Ҝu��-�c�;�^�����X2R]�#��κ�ҴJo��(���W�l>� ��wՇ��r�$6�� �e'(��8�)�!�x��� Y�m�;��ZV� �3���cH�8м��agÞۑE/8�����F4�⥶tY{�X� �Qi��딐�\)��L����L��_bx=�˘�=�Z۲���-�D��U���q ��&� ������W@9:N�C�=k��`��)�r���� ���g֪&r{"�w��Z�Z�j��ͱQ=��� ��cRU��Y6N��=�����n����J�az�9�8w�؝�� q�Vߡ+� ��UQ�(�e>/im�!�Daαy�%�� �~��©_�q��t��I�n�� kt�=MKE�B�� … -ܤ 2T:�F9�SY��ԮG_��FX�� eh��KHJU�6��>��YI!���I��xㇸI%0�Q����"�vxG�W�_��m[��RFp &v�r��� G���=���� c*�qE(���+I�>�L�# �9D�n�F"�ߗ ��"L�����g���. Ŭ.� �+Ψ"R4qV��+�=��ĵ"ҵ��9O��jӢK�:�:{֑�-� I�M����R�ɒ4˼&��̞$8�� ?��[&���7�&�8̩��:D �>��N"�ct���) $�ϙ�=+'E�d8^"Jl�lJT��":����Cn�. �[}�&2�� NR� ��g^�7�l�{�mWKh*����F�Ҿ{��e�Z>���c��}�� f�9�05Y��t���c� ���.w��j �ʔ�H��v�xӽ��/.]�3�X�L�� AJg m��;�)7�J~5���XE� ձi���)#@"g֤Ѩ� _� �un(4�7&����?Ɣ㥶~����� �>����`�'p� … :34:09+01:00 2025-11-13T10:34:09+01:00 cairo 1.18.4 (https://cairographics.org) application/pdf uuid:532629fd-56d6-4fa3-bb4b-335a13828c26 uuid:5d966082-7e35-42a6-9efb-23b824acbfc4 endstream endobj 242 0 obj >stream H��Wko�8��_�O���f�~��6�L���6^t�b�p �Q\?d~� R�-�L��͠h,Q� n�8bcv8&L?���]�0��!?�N>u>Ű�3�4q�g�"[D0E=wD j�~Z7�]��0M{n%�� F�' bs�o�
Rejuvenate Biomed announces RJx-01 Increases Muscle Mass, Muscle Strength and Physical Performance in Sarcopenia Mouse Models - European Pharmaceutical Manufacturer Skip to main content Search Talk to us | Media Portfolio | Latest Issue | My Account linkedin RSS Home Pharma Manufacturing News + Latest Pharmaceutical Manufacturing News Manufacturing News Packaging News Sustainability News Logistics & Distribution News Drug Delivery News Biopharma News Digital Health in Pharma News Regulatory News Finance & Investment News Pharmaceutical Insights + Latest Pharmaceutical Insights Manufact
Rejuvenate Biomed raises a EUR 15.7 million Series B to accelerate clinical development of its sarcopenia treatment for healthy aging | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Rejuvenate Biomed News and Press Releases | PR Newswire Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All Videos Multimedia Gallery Overvi … ated to make your job easier. In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need. LEARN MORE « 1 --> 1 » Making a selection with these dropdown will cause content on this page to change. News listings will update as each option is selected. Items per page: 25 per page 50 per page 75 per page 100 per page Contact PR Newswire Call PR Newswire at 888-776-0942 from 8 AM - 9 PM ET Chat with an Expert Contact Us … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Rejuveron Transitions to Become a Clinical Stage Company as Rejuvenate Biomed Starts Ground-breaking Clinical Trial in Age-Related Muscle Wasting Disease, Sarcopenia – Centenara Labs AG Skip to main content Hit enter to search or ESC to close Close Search Menu What we do Purpose Hallmarks of aging Portfolio Pipeline Who we are People Values & Vision Compliance & Governance How we work Transforming Ideas Life at Centenara Labs News Contact Press releases Rejuveron Transitions to Become a Clinical Stage Company as Rejuvenate Biomed Starts Ground-breaking Clinical Trial in Age-Rel … This platform has resulted in a promising first drug candidate, with the wider application being to deliver therapeutics with a meaningful impact on the treatment and prevention of multiple age-related diseases by tackling their root causes. This strikes right at the heart of Rejuveron’s purpose: making therapies happen for people to stay healthier for longer. About Rejuveron Rejuveron is a clinical-stage biotechnology company creating therapies to improve healthy aging. Its … r Symposium Next Post Researchers at Rejuveron deploy knowledge gained in Nobel prize-winning techniques to crack catalysis conundrums Comments are closed. --> Centenara Labs AG Neuhofstrasse 12 CH-6340 Baar Switzerland +41 44 730 12 90 [email protected] investor relations partnering --> Share Tweet Share Pin © 2026 Centenara Labs AG. All Rights Reserved. | Privacy Policy x-twitter linkedin youtube instagram Close Menu What we do Purpose Hallmarks of aging Portfolio Pip
Rejuvenate Biomed - VLAIO funding €460k to facilitate research Home Team Science History News Events Contact Home Team Science History News Events Contact Home News VLAIO funding €460k to facilitate research VLAIO funding € 460k to facilitate research Press Release – Life Sciences & Biotechnology Antwerp, Belgium - 10 August 2018 Rejuvenate Biomed awarded €460,000 grant from VLAIO to accelerate drug development for healthy aging CMAST was instrumental in the Grant proposal submission Rejuvenate Biomed - a biomedical company that researches the biology of aging and applies this knowledge to ide … delay the aging process – today announces it has been awarded a €460K Research Grant by Flanders Innovation & Entrepreneurship (VLAIO). The grant will be used to gain new insights in the aging pathways – which will ultimately contribute to the clinical research and the exploitation of a first lead candidate. Rejuvenate Biomed, founded in 2017, aims to become a frontrunner in healthy aging prescription products which positively impact the health span, i.e. the length of t … and develop these drugs for use in humans. We are very pleased to receive this grant from VLAIO which will allow us to accelerate our research in this field .” Grant writing was supported by CMAST, a Consultancy and Project Management company in Life Sciences. Glenn Van Dael, CEO of CMAST : “ Age-related diseases – such as arthritis, diabetes mellitus, cancer and heart diseases - result in an enormous burden on the individual, the economy and the healthcare system. At CMAST, … and are happy to have contributed with the successful submission of this VLAIO grant proposal .” NOTES FOR THE EDITOR: About Rejuvenate Biomed Rejuvenate Biomed, an independent Belgium based R&D company and spin-out from Janssen Pharmaceutical companies of Johnson and Johnson, was established in October 2017. The Company aims to increase the healthy years of life, also referred to as health span, by repositioning prescription drugs to the field of healthy aging. Rejuvena
Rejuvenate Biomed and SAS tap AI to develop disease-agnostic drug repurposing discovery tools | SAS Iceland Skip to main content Software Learn Support Partners About Us SAS Innovate Try SAS Software SAS Viya Platform SAS Viya Platform Overview Data Management Explore and Model Deploy Insights AI Governance How to Buy SAS®9 to Viya Solutions Solutions Artificial Intelligence (AI) Fraud & Compliance IoT Marketing Risk Management All Products & Solutions Industries Industries Banking Public Sector Insurance Health Care Life Sciences Manufacturing All Industries Explore Explore Try/Bu
Rejuvenate Biomed - Rejuvenate Biomed, the NIHR Leicester BRC, and Wellcome Leap partner for Phase 2 Study in COPD-related sarcopenia Home Team Science History News Events Contact Home Team Science History News Events Contact Home News Rejuvenate Biomed, the NIHR Leicester BRC, and Wellcome Leap partner for Phase 2 Study in COPD-related sarcopenia Press Release Rejuvenate Biomed, the NIHR Leicester BRC, and Wellcome Leap partner for Phase 2 Study in COPD-related sarcopenia. The Phase 2 double-blind placebo-controlled clinical trial will evaluate the potential of RJx-01 to maintain muscle integ … bility will be assessed. The clinical study is enabled by a multimillion dollar award from Wellcome Leap ’s Dynamic Resilience program (co-funded by Temasek Trust). The Dynamic Resilience program aims to improve biological resilience in clinically vulnerable people at-risk of adverse outcomes after a stressor event, by identifying resilience biomarkers and mechanisms and facilitating proof-of-concept studies and clinical trials of potential preventative interventions. This st
Rejuvenate Biomed | MTEC MTEC Focus Areas Who we serve Solicitations Patents About Us Explore Join MTEC Log In Life Sciences / Companies Rejuvenate Biomed Clinical-stage biotech focused on discovering and developing combination small-molecule therapeutics to address age-related diseases. The company uses validated AI-driven in silico screening and an in vivo C. elegans screening platform to generate combination drug candidates, advances assets through preclinical models and human clinical trials, and pursues partnerships and licensing for platform and asset development. Industries N/A Nr. of E
Rejuvenate Bio and SAS to develop drug repurposing tool - Drug Discovery World (DDW) Drug Discovery World (DDW) About Us | Subscribe Free | Media Info | Contact Us | Log In News Exclusive Content Features Opinion Market Reports Trends & Analysis Start-up Zone DDW eBooks Business & Investment Regulatory Events Webinars Resources Magazine Digital Issues Archive Multimedia Videos Podcasts Topic filter: Cancer Research Immunology / Virology & Vaccines Advanced Therapies Neuroscience Multiomics Artificial Intelligence Automation & Robotics Therapeutic Antibodies Microbiome Drug Discover
Rejuvenate Biomed - BIO International Convention | BIO Skip to main content --> Policy Get Involved Join BIOAction View Advocacy Toolkit Patient Advocacy Human Health Cost and Value of Biopharmaceuticals Antimicrobial Resistance Vaccines & Biodefense Drug Development & Review International Global Markets & Trade Multilateral Organizations Intellectual Property Science & Regulatory All Policy Patient Advocacy Join BIO as we champion for bringing new treatments to patients with serious medical conditions and to support policies that promote innovation and improve patient access. Member Membershi
Rejuvenate Biomed and SAS tap AI to develop disease-agnostic drug repurposing discovery tools | SAS Zurück zum Hauptinhalt Software Learn Support Partner Über SAS SAS ausprobieren Software SAS Viya Platform SAS Viya Platform Mehr über SAS Viya erfahren Testen und kaufen Lösungen Lösungen Fraud IoT Marketing Risikomanagement Alle Produkte & Lösungen Branchen Branchen Banken Öffentliche Verwaltung Versicherungen Life Sciences Einzelhandel & Konsumgüter Alle Branchen Vertiefen Vertiefen Testen / kaufen Warum SAS? Referenzen Consulting Learn Training Training
#thebiohub #biotech #leadership #healthyaging #drugdevelopment #lifesciences | Rejuvenate Biomed LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to … Agentic AI in Drug Discovery Moderator: Stephanie Oestreich (Myeloma Investment Fund) - From Complexity to Clarity: Single-Cell, Spatial, and Multi-Omics Moderator: Isha Parikh (Mount Sinai) BioTechX USA continues to offer a full platform for visibility and influence across the ecosystem, including thought leadership speaking slots, panel discussions, and exhibition opportunities for companies looking to position themselves as leaders. For those shaping the future of biotech
Rejuvenate Biomed - News Home Team Science History News Events Contact Home Team Science History News Events Contact Home News Stay up-to-date about our progress and other news Preclinical data reviewed by Scientific Advisory Board The SAB concluded that the preclinical data of RJx-01 demonstrate proof-of-principle for sarcopenia, and show potential in multiple other muscle- and non-muscle-related disorders. LEARN MORE Dr. Ajit Shetty appointed as Chair of the Board Rejuvenate Biomed appoints Dr. Ajit Shetty as Chair of the Board of Directors. As a veteran of the life sciences industry, Dr. Sh
Rejuvenate Biomed appoints life sciences leader Dr. Ajit Shetty as Chair of the Board of Directors to help guide international ambitions Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview … luding Agile Therapeutics, Actinium Pharmaceuticals, and reMYND), as well as VC fund Newton Biocapital. In recognition of his unique services as a leader in the life sciences industry, Dr. Shetty was awarded the Right Honourable Sir and Title of Baron by King Albert II of Belgium in 2008. He was granted the Lifetime Achievement Award in India , his country of birth, in 2010. Dr. Shetty was also elected "Manager of the Year 2004" by Belgian economic magazine Trends. Dr. Ajit S … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Empowered Patient Podcast: Developing Combination Therapies Targeting Hallmarks of Aging to Address Multiple Age-Related Diseases with Dr. Ann Beliën Rejuvenate Toggle navigation About Contact Episodes All Episodes Categories Addiction Aging and Seniors Allergies Big Data Big Data and AI Cancer Cardiology CBD Cell Therapy Central Nervous System Clinical AI Clinical Trials COVID-19 Depression Dermatology Diabetes Diagnostics Dietary Supplements Digital Health Doctors Empowering Patients Epigenetics Gastrointestinal Disorders general Gene Therapy Genetics GIS Healthcare Investing Healthcare Prot … ch we have checked if they’re safe for an older population and also for chronic application. That information about these compounds, how they exactly work, goes into our system. The system sees if now these compounds theoretically have the ability to have an impact on the hallmarks of aging. If this is the case, the system will predict a combination that can allow you to impact as many different elements as possible. With that combination, we then check in worms, little worms … ith Karen Jagoda is a window into the latest innovations in digital health, the application of AI for administrative and clinical uses, the changing dynamic between doctors and patients, personalized medicine, cell and gene therapies, aging in place, wearables and sensors, clinical trials and advances in clinical research, payer trends, transparency in the medical marketplace and challenges for connected health entrepreneurs. This show continues to evolve driven by the conver
Episode 127 - Ann Belien - Fou... — The BioHub - by Avetix — Apple Podcasts Szukaj Ekran główny Nowości Rankingi Szukaj 10 marca 28 min Episode 127 - Ann Belien - Founder and CEO Rejuvenate Biomed The BioHub - by Avetix Odtwórz Ann is the Founder and CEO of Rejuvenate Biomed , a clinical-stage biotechnology company developing combination therapies aimed at targeting the biological mechanisms behind age-related diseases. With more than two decades of experience in pharmaceutical research and development, she has built a career focused on translating cutting-edge science into therapies that can
Path to Healthy Aging: Pioneering Age-Related Disease Therapies Rejuvenate Biomed's Ann Beliën | Rejuvenate Biomed LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or
Episode 127 - Ann Belien - Founder and CEO Rejuvenate Biomed - The BioHub - by Avetix | Podcast on Spotify
The Path to Healthy Aging: Pioneering Therapies for Age-Related Diseases with Rejuvenate Biomed's Ann Beliën - Xtalks Thursday, June 25, 2026 | 1pm EDT: How To Strengthen Launch Strategies With Medical-Commercial Collaboration X Skip to content LOGIN JOIN Webinars Industries All Life Sciences Pharma Biotech Medtech Healthcare Research Food News & Features All Xtalks Editorial News Blogs Videos Quizzes & Polls Pharmaville Xtalks Spotlight Life Science Podcast Xtalks Clinical Edge™ Community Features Peer Circles Industry Jobs Search Jobs Post Job Talent Acquisition & Brandin … of your data Security We take precautions to protect your information. When you submit sensitive information on our Site, your information is protected both online and offline. We use encryption to protect sensitive information transmitted online and we protect your information offline. Only our employees who need your information to perform a specific task (for example, customer service or marketing) are granted access to personally identifiable information. The computers an … ing address, address, email address and telephone numbers. Resume Data includes application materials and answers to screener questions given to employers through the Xtalks Job Platform and answers to any questionnaires. This information may be associated with a profile. Transaction Data includes details about payments and other details of products and services bought from us. Technical Data includes internet protocol (IP) address, login data, browser type and version, time … on xtalks.com e.g., searches you run or webinars and jobs you click on when you apply to jobs or for webinars, use screener or assessment questions or log in from third party sites information we learn about you through our relationship and the way you interact with us In some circumstances we may also receive information from: regulatory bodies other companies supplying services to us data analytics to improve our website, products/services, marketing, customer relationships … imited circumstances, for example, repeated requests for further copies, we may apply an administration fee. Rectification of personal data – this right enables you to have any incomplete or inaccurate data we hold about you corrected, though we may need to verify the accuracy of the new data you provide to us. Erasure of personal data – Yo
Rejuvenate Biomed - Key research collaboration with Prof. Rafael de Cabo Home Team Science History News Events Contact Home Team Science History News Events Contact Home News Key research collaboration with Prof. Rafael de Cabo Key research collaboration with Prof. Rafael de Cabo Rejuvenate Biomed established a Cooperative Research & Development Agreement (CRADA) with Dr. Rafael de Cabo, MD, PhD, Professor at the NIA`s Translational Gerontology Branch, to evaluate the effects on the characteristics of aging, including overall health, survival & resilience in mice. This intensive precli
AI at the forefront of age-related disease treatment | Article | Drug Target Review Your browser is not supported Sorry but it looks as if your browser is out of date. To get the best experience using our site we recommend that you upgrade or switch browsers. Find a solution Skip to main content Skip to navigation Site name Site name Mast navigation Become a member Sign In Search our site Search our site Search Menu Close menu Home News Oncology AI Topics Back to parent navigation item Topics Technology Resources Diseases Drugs and therapies Research and development Tools and techniques Busine … h the University of Leicester, UK, and is funded through a multi-million-dollar award from Wellcome Leap, a non-profit organisation established by Wellcome Trust. The second study will focus on patients treated with GLP-1 receptor agonists, who experience muscle-related side effects. Partnerships fuelling growth At Rejuvenate Biomed, we believe that collaboration is essential to advancing scientific progress. The complexity of ageing and age-related diseases requires expertis … y of life-limiting, but rather manageable and treatable conditions. Through the application of AI, precision medicine, and innovative therapies like RJx-01, we are working towards a future where ageing itself can be addressed at a biological level, before it leads to debilitating disease. Our AI-powered platforms give us the tools to fundamentally change how we understand and treat ageing and develop safe and effective drugs for patients that need them most. The real-world im
Rejuvenate Biomed - Science Home Team Science History News Events Contact Home Team Science History News Events Contact Home Science Learn about our unique platform-driven approach Biology of aging Growing old is a natural and beautiful part of life, shaped by experiences and wisdom. Yet aging is a complex, multifactorial phenomenon that impacts many interrelated biological pathways. At Rejuvenate Biomed, we embrace the complexity of aging and focus on the healthcare challenge posed by age-related diseases. Our approach to drug discovery and development starts from navigating the pathways that
Rejuvenate Biomed Home Team Science History News Events Contact Home Team Science History News Events Contact AI-enabled clinical-stage biotech dedicated to the discovery and development of therapeutics to impact the onset of multiple age-related diseases How we generate value Building an exciting pipeline Rejuvenate Biomed One-Pager Highlights Rejuvenate Biomed Completes Recruitment in Phase 2 Trial Assessing First-in-Class Multi-Pathway Therapeutic RJx-01 in COPD-Induced Sarcopenia Fully recruited Phase 2 trial evaluates RJx-01 in older adults with COPD-induced muscle weakness and sarcopenia
%PDF-1.5 %���� 973 0 obj > endobj xref 973 49 0000000016 00000 n 0000003411 00000 n 0000003525 00000 n 0000004048 00000 n 0000004389 00000 n 0000005125 00000 n 0000005546 00000 n 0000006120 00000 n 0000006158 00000 n 0000006521 00000 n 0000006635 00000 n 0000007183 00000 n 0000007752 00000 n 0000008398 00000 n 0000008651 00000 n 0000008993 00000 n 0000009404 00000 n 0000009865 00000 n 0000010668 00000 n 0000011293 00000 n 0000011883 00000 n 0000012535 00000 n 0000013098 00000 n 0000013696 00000 n 0000014295 00000 n 0000015001 00000 n 0000057647 00000 n 0000058242 00000 n 0000060893 00000 n 000 … PANTONE Blue 072 CV SPOT 100.000000 CMYK 100.000000 79.000002 0.000000 0.000000 application/pdf SachsAssociates_WHITE xmp.did:83f9c140-f25d-4648-8432-1d0fcaa93b68 uuid:6c5e450b-6715-4670-8d9c-02a690f786b8 xmp.did:83f9c140-f25d-4648-8432-1d0fcaa93b68 proof:pdf converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:83f9c140-f25d-4648-8432-1d0fcaa93b68 2018-02-20T17:43:38+02:00 Adobe Illustrator CC 2015 (Windows) / Document Adobe PDF library 15. … u��!�PQ3 &��wg�lцh�ֆ,f�����U�v�fi�)"c� &�A�`� '0*�F�Hd�k �gV�3Vh�Mf�Y�3 �2�RFPbP� H\�F��f�T�0/�٬� �M>�C���chZ��3lٞي�T�ȕ�TJH�T�ݓ��I���� �;��Ԋ��JXJN&AT�[7i!�Y��lύgfzP�RL3uJU�Pd�5*L�P$�X�m� h�;37��3f����n-�kթ(�K���MF�H$��$^�5I�Ҏ4�:�[ �Fb�jOhk4C|�3F~V�ݭ�.�2v1�$�9 �f���*]�FF��@�p�)f����Kf�!���r�5mZ�mRd��m'4���T̚ ���ɟٱ+R�TIK3w�$�nC���7� 3ڳf�ݛ�T������F�1��WXV�ޟ��| � � U8f�4I,���sMD�k �I0A�u ̕͞Ւ�Rά̐�����Hݘ�G ϐpf,���r��)fj B�B 2#w���"g�W�ªXF … Huk0U� H�#vh)-(%��5A�.ͻ ��i4�cF���0A endstream endobj 398 0 obj >stream application/postscript AYOXXA_2017_Biosystems_cmyk user 2017-06-19T17:39:13+02:00 2017-06-19T17:39:13+02:00 2017-06-19T17:39:13+02:00 Adobe Illustrator CS6 (Macintosh) xmp.iid:0A8011740720681183D1A5BCC726C604 xmp.did:0A8011740720681183D1A5BCC726C604 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:b58dd17a-8eaa-d141-99ad-9e060b9406ce xmp.did:574DB0143C206811822AFD86FF2641FF uuid:5D20892493BFDB … 19-12cc8c250576 xmp.did:9BA972BD3420681183D1DC862100CF49 default converted from application/x-indesign to application/pdf Adobe InDesign CC 2017 (Macintosh) / 2018-08-29T15:53+02:00 application/pdf Adobe PDF Library 15.0 False endstream endobj 746 0 obj > endobj 747 0 obj >stream H��W�r���OU�A��I*��_ l� ���{\ƕ�\����v4�/��Ef$$F#�ؾ� y`l�
Rejuvenate Biomed - Research and Design | The Org Platform Enrich Pricing Log in Sign up Rejuvenate Biomed Teams Research and Design Unverified Research and Design 3 people · 0 jobs The Research and Design team at Rejuvenate Biomed focuses on innovating and optimizing drug formulations for healthy aging therapies. The team collaborates to conduct experimental research, develop compelling visual representations of their findings, and ensure lab facilities are well-managed and equipped for cutting-edge experiments. By integrating scientific expertise with creative design, they aim to repositio
%PDF-1.7 %���� 1 0 obj >/Metadata 3789 0 R/ViewerPreferences 3790 0 R>> endobj 2 0 obj > endobj 3 0 obj >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 960 540] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x�U�1 �0��@�Û �K�"�UKqZ:tQq����Oc�-.oxw�}��2�M� � ��ޜ�/7 endstream endobj 5 0 obj > endobj 6 0 obj > stream x��݉����/�>o�t���4�lBӲ��˾ ��{�/���Ȣ����@2�x��qf�d����131!љA���%�M&�(4M�����ϧ�eY�*��yO�����sJJz����1���Z?s����^�p��֓ �9���W�����?�����O}���wV�e����nnl�ZU�7���H�� �?��� ���%R������|�6��9�e�GIi���/�vz���z���we��_��0/)-�~�t� … �b]�y@aju�M}F��Z� { �7m� �%�z��;��^��le44��i7]��l��Ee�۬��ϱ�^I������� ���EkrfP��&&q��z�^M���r���]n�w�#�[��g�Q*e����f��`�{�~b�[�ߨ I �b�tn�����删���0�Xָ�_o�m��I������#��?���~�� t̼��9��I���V�Um���g��=5�����k�����Օ��� ַ�~���U༘wH��F�9�k�\b����t�L�Kq�r1�{D���w�;������=A^�W���?W~�?��X��ο�eN,}gc�H�s�}�O�+��\�;*s~�c}K2,���C���;hn�N���Edz~�Z��.�&O�}���^��o�(�n��WZ9s�w�}�����G�~l\�8K6��@��x7Sђ ˂���>[��f�H�;w����/������gUf1sǧc^-��� ǵ�ͣ�VK��L�X���~��k
Agenda - Day 2 | BIO-Europe Spring You need to enable JavaScript to run this app. This site is part of the Informa Connect Division of Informa PLC Informa PLC About Us Investor relations Talent This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067. March 23–25, 2026 FIL (Feira Internacional de Lisboa), Lisbon, Portugal March 31 – April 1, 2026 | Digital Partnering Home home What to expect expand_more Who attends? Receptio … e cultural ambition into operational results, and how similar organisations can apply these principles to strengthen pipeline delivery, resilience, and long-term competitiveness. Nick Petschek - Managing Director , Kotter Diego Ardigo - Head of Research & Development , Chiesi Group 16:00 - 16:45 Shifting tides: Redefining biotech partnerships Location: Exhibit Hall Stage The industry is evolving toward collaborative models that transcend traditional vendor relationships, … ; CEO , Metatissue 16:00 - 16:15 Drug Delivery: NanoSyrinx Ltd NanoSyrinx is an award-winning, discovery stage biotechnology company based in the UK. We are using synthetic biology approaches to develop protein Nanosyringes as a completely novel modality for targeted, intracellular delivery of protein and peptide biologic drugs. Our vision at NanoSyrinx is to unlock the interior of the cell and the myriad therapeutic opportunities within that are currently difficult (or impos
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
%PDF-1.4 %���� 852 0 obj > endobj 851 0 obj >stream PScript5.dll Version 5.2.2 2026-06-24T22:22:04-07:00 2026-02-18T14:25:54-08:00 2026-06-24T22:22:04-07:00 application/pdf Muscle Ageing and Sarcopenia Study (MASS) Lifecourse: a unique resource for understanding skeletal muscle ageing across adulthood Administrator Acrobat Distiller 8.1.0 (Windows) uuid:fe52a4b6-1dd1-11b2-0a00-4b09275dc400 uuid:fe52a4be-1dd1-11b2-0a00-810000000000 endstream endobj 850 0 obj > endobj 13 0 obj > endobj 2 0 obj > endobj 59 0 obj > endobj 62 0 obj > endobj 183 0 obj >/ExtGState >/Font >/ProcSet[/PDF/Text]>>/Type/P
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Rejuvenate Biomed - History Home Team Science History News Events Contact Home Team Science History News Events Contact Home History Discover our story We envision a future where people stay healthy for life. Rejuvenate Biomed is a Belgian clinical-stage biomedical company founded in 2017 by Ann Beliën, PhD, after nearly two decades of experience with Janssen Pharmaceutical Companies of Johnson & Johnson. In 8.5 years Ann has built a team of twenty well-experienced drug development experts, enthusiastically engaged to make a difference in the longevity field. Rejuvenate Biomed's team has m
Rejuvenate Biomed Completes Recruitment in Phase 2 Trial Assessing First-in-Class Multi-Pathway Therapeutic RJx-01 in COPD-Induced Sarcopenia - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufac … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Rejuvenate Biomed Completes Recruitment in Phase 2 Trial Assessing First-in-Class Multi-Pathway Therapeutic RJx-01 in COPD-Induced Sarcopenia June 1, 2026 | 6 min read Twitter LinkedIn Facebook Email Print Fully recruited Phase 2 trial evaluates RJx-01 in older adults with COPD-induced muscle weakness and … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Rejuvenate Biomed - €15.7 million Series B round secured Home Team Science History News Events Contact Home Team Science History News Events Contact Home News €15.7 million Series B round secured Rejuvenate Biomed secures €15.7 million Series B round Heusden-Zolder, Belgium, Schlieren, Zürich, Switzerland, and Luxembourg, Grand Duchy of Luxembourg, 12 October 2021 – Rejuvenate Biomed NV (‘Rejuvenate’), a biomedical company developing novel combination drugs for age-related diseases, today announces a EUR 15.7 million Series B round. The funding is being used to accelerate the clinical developm … This platform has resulted in a promising first drug candidate, with the wider application being to deliver therapeutics with a meaningful impact on the treatment and prevention of multiple age-related diseases by tackling their root causes. This strikes right at the heart of Rejuveron’s purpose: making therapies happen for people to stay healthier for longer.” About Rejuvenate Biomed Rejuvenate Biomed is an independent Belgian biomedical company established in October 2017 … pital III Vesalius Biocapital III is a specialist life sciences venture capital fund in line with predecessor funds Vesalius Biocapital I and Vesalius Biocapital II, which have supported life sciences companies since 2007. Vesalius Biocapital III, launched in April 2017, announced a final close with EUR 120 million in commitments. The fund targets later-stage European life science companies in drug development, medtech, diagnostics and digital health. The specialist team is b
Rejuvenate Biomed and SAS tap AI to develop disease-agnostic drug repurposing discovery tools | SAS Skip to main content Software Learn Support Partners About Us SAS Innovate Try SAS Software SAS Viya Platform SAS Viya Platform Overview Data Management Explore and Model Deploy Insights AI Governance How to Buy SAS®9 to Viya Solutions Solutions Artificial Intelligence (AI) Fraud & Compliance IoT Marketing Risk Management All Products & Solutions Industries Industries Banking Public Sector Insurance Health Care Life Sciences Manufacturing All Industries Explore Partners Explore Try/B
Rejuvenate Biomed Home Team Science History News Events Contact Home Team Science History News Events Contact AI-enabled clinical-stage biotech dedicated to the discovery and development of therapeutics to impact the onset of multiple age-related diseases How we generate value Building an exciting pipeline Rejuvenate Biomed One-Pager Highlights Rejuvenate Biomed Completes Recruitment in Phase 2 Trial Assessing First-in-Class Multi-Pathway Therapeutic RJx-01 in COPD-Induced Sarcopenia Fully recruited Phase 2 trial evaluates RJx-01 in older adults with COPD-induced muscle weakness and sarcopenia